Literature DB >> 19656025

Full-mouth ultrasonic debridement associated with amoxicillin and metronidazole in the treatment of severe chronic periodontitis.

Erica Del Peloso Ribeiro1, Sandro Bittencourt, Iriana Carla Junqueira Zanin, Glaucia Maria Bovi Ambrosano, Enilson A Sallum, Francisco H Nociti, Reginaldo Bruno Gonçalves, Márcio Zaffalon Casati.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the adjunctive clinical, microbiologic, and immunologic effects of the systemic administration of amoxicillin and metronidazole in the full-mouth ultrasonic debridement of patients with severe chronic periodontitis.
METHODS: Twenty-five patients presenting at least eight teeth with probing depth (PD) > or =5 mm and bleeding on probing (BOP) were selected and randomly assigned to full-mouth ultrasonic debridement + placebo (control group) or full-mouth ultrasonic debridement + amoxicillin and metronidazole (test group). The clinical outcomes evaluated were visible plaque index, BOP, position of the gingival margin, relative attachment level (RAL), and PD. Real-time polymerase chain reaction (PCR) was used for quantitative analysis of Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans), Porphyromonas gingivalis, and Tannerella forsythia (previously T. forsythensis). The enzyme-linked immunosorbent assay (ELISA) technique permitted the detection of prostaglandin E(2,) interleukin-1beta, and interferon-gamma levels in gingival crevicular fluid. All parameters were evaluated at baseline and at 3 and 6 months post-treatment.
RESULTS: At 6 months, the test treatment resulted in lower BOP and an additional reduction (0.83 mm) in PD (P <0.05). Data also showed RAL gain > or =2 mm at 43.52% of sites in control patients compared to 58.03% of sites in test patients (P <0.05). However, both groups had similar mean RAL gain (1.68 and 1.88 mm for the control and test groups, respectively). Real-time PCR and ELISA failed to identify significant differences between the groups.
CONCLUSIONS: Both treatments resulted in significant clinical improvements; however, there was a slight, but significantly greater, improvement in BOP and the percentage of sites with PD > or =5 mm exhibiting RAL gain > or =2 mm in the test group. Nevertheless, no improvement in the microbiologic or immunologic outcome was observed with the adjunctive use of systemic amoxicillin and metronidazole.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656025     DOI: 10.1902/jop.2009.080403

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  11 in total

1.  Full-mouth ultrasonic debridement associated with povidone iodine rinsing in GAgP treatment: a randomised clinical trial.

Authors:  Hugo Felipe do Vale; Renato Corrêa Viana Casarin; Tiago Taiete; Gláucia Maria Bovi Ambrosano; Karina Gonzales Silvério Ruiz; Francisco Humberto Nociti; Enílson Antônio Sallum; Márcio Zaffalon Casati
Journal:  Clin Oral Investig       Date:  2015-04-16       Impact factor: 3.573

2.  The adjunctive effect of photodynamic therapy for residual pockets in single-rooted teeth: a randomized controlled clinical trial.

Authors:  Gisele N Campos; Suzana P Pimentel; Fernanda V Ribeiro; Renato C V Casarin; Fabiano R Cirano; Cintia H C Saraceni; Márcio Z Casati
Journal:  Lasers Med Sci       Date:  2012-07-20       Impact factor: 3.161

3.  [Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis].

Authors:  Yin Bai; Yuan-Liang Bai; Jing Lai; Jiao Huang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

Review 4.  An estimate of pocket closure and avoided needs of surgery after scaling and root planing with systemic antibiotics: a systematic review.

Authors:  Mirela Kolakovic; Ulrike Held; Patrick R Schmidlin; Philipp Sahrmann
Journal:  BMC Oral Health       Date:  2014-12-22       Impact factor: 2.757

5.  Multilevel analysis of bacterial counts from chronic periodontitis after root planing/scaling, surgery, and systemic and local antibiotics: 2-year results.

Authors:  Ibrahimu Mdala; Ingar Olsen; Anne D Haffajee; Sigmund S Socransky; Birgitte Freiesleben de Blasio; Magne Thoresen
Journal:  J Oral Microbiol       Date:  2013-07-09       Impact factor: 5.474

6.  Detection of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans after Systemic Administration of Amoxicillin Plus Metronidazole as an Adjunct to Non-surgical Periodontal Therapy: A Systematic Review and Meta-Analysis.

Authors:  Aleksandar Dakic; Adrien Boillot; Cyrille Colliot; Maria-Clotilde Carra; Sébastien Czernichow; Philippe Bouchard
Journal:  Front Microbiol       Date:  2016-08-19       Impact factor: 5.640

Review 7.  The concomitant administration of systemic amoxicillin and metronidazole compared to scaling and root planing alone in treating periodontitis: =a systematic review=.

Authors:  Dina Zandbergen; Dagmar Else Slot; Richard Niederman; Fridus A Van der Weijden
Journal:  BMC Oral Health       Date:  2016-02-29       Impact factor: 2.757

8.  One year results of a randomized controlled clinical study evaluating the effects of non-surgical periodontal therapy of chronic periodontitis in conjunction with three or seven days systemic administration of amoxicillin/metronidazole.

Authors:  Raluca Cosgarea; Christian Heumann; Raluca Juncar; Roxana Tristiu; Liana Lascu; Giovanni E Salvi; Nicole B Arweiler; Anton Sculean
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

9.  Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis.

Authors:  Shivi Khattri; Sumanth Kumbargere Nagraj; Ankita Arora; Prashanti Eachempati; Chandan Kumar Kusum; Kishore G Bhat; Trevor M Johnson; Giovanni Lodi
Journal:  Cochrane Database Syst Rev       Date:  2020-11-16

10.  Microbial profiles at baseline and not the use of antibiotics determine the clinical outcome of the treatment of chronic periodontitis.

Authors:  S Bizzarro; M L Laine; M J Buijs; B W Brandt; W Crielaard; B G Loos; E Zaura
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.